Dayvigo therapeutic indications: DAYVIGO is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. For full information please refer to Dayvigo SPC as approved by the Israeli MOH.

References: 1. Rosenberg R, Murphy P, Zammit G et al. Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder — a phase 3 randomized clinical trial. JAMA Network Open 2019; 2 (12): e1918254. | 2. Yardley J, Kärppä M, Inoue Y et al. Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Med 2021; 80: 333–342 | 3. DAYVIGO (lemborexant) SPC as approved by the Israeli MOH. | 4. Murphy P, Kumar D, Zammit G, Rosenberg R, Moline M. Safety of lemborexant versus placebo and zolpidem: effects on auditory awakening threshold, postural stability, and cognitive performance in healthy older participants in the middle of the night and upon morning awakening. J Clin Sleep Med. 2020 May 15;16(5):765-773. doi: 10.5664/jcsm.8294. Epub 2020 Feb 6. PMID: 32022664; PMCID: PMC7849806. | 5. Dayvigo PSUR, January 2024. | 6. Margaret Moline, Gary Zammit, Jane Yardley, Kate Pinner, Dinesh Kumar, Carlos Perdomo & Jocelyn Y. Cheng (2021) Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials, Postgraduate Medicine, 133:1, 71–81, DOI: 10.1080/00325481.2020.1823724 | 7. Sogawa R, Emoto A, Monji A, et al, Association of orexin receptor antagonists with falls during hospitalization. J Clin Pharm Ther. 2022;47:809–813. doi:10.1111/jcpt.13619

Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il/ or emailed to Eisai Israel at: [email protected]

*As indicated in the SPC, there is no limitation on the duration of administration time † Based on a retrospective study including a total of 6989 patients

IL-DAY-25-00023